2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1482

Web-Based PILOT Intervention Study to Improve Cardiovascular Risk Knowledge Among Rheumatoid Arthritis Patients
Abstract Number: 1483

Elevated Anti-Cyclic Citrullinated Peptide Antibody Titer Is Associated with Increased Cardiovascular Risk
Abstract Number: 1484

Exploring the Link Between RA Disease Activity, Lipid Levels, and Cardiovascular Disease in an Early Inflammatory Arthritis Cohort
Abstract Number: 1485

Generation of New Carotid Plaque Is Determined By the Prexisting Carotid Atherosclerosis and Ongoning Disease Activity of Rheumatoid Arthritis
Abstract Number: 1486

Associations Between Heart Rate Adjusted ST Segment and Heart Rate Variability in Patients with Rheumatoid Arthritis
Abstract Number: 1487

Comparison Between Intima-Media Thickness and Coronary Artery Tomography in Subclinical Atheroesclerosis Detection in Rheumatoid Arthritis
Abstract Number: 1488

Comparison Between Carotid Ultrasonography and Coronary Artery Calcification Score to Detect Subclinical Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 1489

Incident Hypertension and Associated Factors in a Hispanic Group with Rheumatoid Arthritis
Abstract Number: 1490

Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 1491

M-Ficolin and MAp44 As Potential Markers of Subclinical Cardiovascular Comorbidity; Cardiac Evaluation By Coronary Computer Tomography and Myocardial Deformation of Left Ventricle in Early Rheumatoid Arthritis Patients
Abstract Number: 1492

Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Abstract Number: 1493

Screening Patterns for Hyperlipidemia Among Patients with Rheumatoid Arthritis Based on Patterns of Care from By Primary Care Physicians, Rheumatologists or Both
Abstract Number: 1494

Myocardial Structure, Function, and Fibrosis in Patients with Rheumatoid Arthritis and Matched Control Subjects
Abstract Number: 1495

Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project
Abstract Number: 1496

Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].